72 results
Page 2 of 4
424B5
ha0f5enk3
24 Mar 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
97w 1yt70
26 Jan 22
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
8:15am
424B5
qxf209sg 8rk90jz1xaw
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
9wbk271
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
8-K
EX-99.1
65n7h
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
236 sp4dj9lrumnpi
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
424B3
c6iquf cn
12 Apr 21
Prospectus supplement
1:44pm
S-3
7oj2vs6ny hbt7ki
2 Apr 21
Shelf registration
12:00am
8-K
EX-99.1
9ggptj6m
25 Mar 21
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
12:00am
8-K
EX-99.1
5cx 95fbg
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
4nhe7jknvf7yqbymrao
11 Jan 21
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
1:35pm
8-K
EX-99.1
53stz9hln0woda
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am